ESC Premium Access

Controversies in anti-platelet therapy

Event: ESC CONGRESS 2019
Topic: Pharmacotherapy
Session type: Debate Session
Date: 1 September 2019
Time: 14:30 - 15:40

Congress Session

6 presentations in this session

P2Y12 inhibition should be started at the time of NSTEMI diagnosis - PRO.

Speaker: Professor M. Valgimigli (Lugano, CH)
Thumbnail

P2Y12 inhibition should be started at the time of NSTEMI diagnosis - CON.

Speaker: Professor G. Montalescot (Paris, FR)
Thumbnail

P2Y12 inhibition should be started at the time of NSTEMI diagnosis -Discussion

Thumbnail

Duration of DAPT should be beyond 1 year post acute coronary syndrome - PRO.

Speaker: Doctor M. Bonaca (Aurora, US)
Thumbnail

Duration of DAPT should be beyond 1 year post acute coronary syndrome - CON.

Speaker: Associate Professor G. De Luca (Novara, IT)
Thumbnail

Duration of DAPT should be beyond 1 year post acute coronary syndrome - Discussion

Thumbnail

4 speakers from this session

Professor Marco Valgimigli

Cardiocentro Ticino Foundation, Lugano (Switzerland)
22 presentations
1 follower

Professor Gilles Montalescot

Sorbonne University, Paris (France)
24 presentations
1 follower

Doctor Marc Bonaca

University of Colorado, Aurora (United States of America)
25 presentations
0 follower

Associate Professor Giuseppe De Luca

University of Eastern Piedmont, Novara (Italy)
1 presentation
0 follower

This platform is supported by

logo Novo Nordisk